

Dynamic variation and prognostic value of weight loss during radiotherapy in nasopharyngeal carcinoma: A large-scale cohort study

Ya-Nan Jin

Sun Yat-sen University Cancer Center

Tian-Liang Xia

Sun Yat-sen University Cancer Center

Dong-Mei Mai

Sun Yat-sen University Cancer Center

Ji-Jin Yao

Fifth Affiliated Hospital of Sun Yat-sen University

Chang Jiang

Sun Yat-sen University Cancer Center

Kun-Wei Peng

Sun Yat-sen University Cancer Center

Ya-Fei You

Sun Yat-sen University Cancer Center

Lei Wang

Sun Yat-sen University Cancer Center

Wen-Zhuo He

Sun Yat-sen University Cancer Center

Liang-Ping Xia (✉ xialp@sysucc.org.cn)

Sun Yat-sen University Cancer Center

Research

Keywords: Nasopharyngeal carcinoma, radiotherapy, weight loss, dynamic variation, prognostic value

Posted Date: October 28th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-96692/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: We investigated the dynamic variation and prognostic value of weight loss among nasopharyngeal carcinoma (NPC) patients.

Methods: 1149 newly diagnosed NPC patients receiving radical radiotherapy (RT) were retrospectively analyzed. Patients' weights were measured at initiation of RT and every week during RT. Recursive partitioning analyses (RPAs) were utilized to determine cut-off value for rate of weight loss (RWL). To assess predictive value of RWL survival analysis was performed. Disease-free survival (DFS) was our primary endpoint. Secondary endpoints included locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), and overall survival (OS).

Results: RWLs were 0%, 0%, -1.54%, -2.86%, -4.11%, -5.98%, -6.56% at 1st, 2nd, 3rd, 4th, 5th, 6th, and 7th week of RT, respectively. RWL optimal threshold with respect to DFS was 5.3% based on RPAs. Thus, a consistent threshold of -5% (>-5% versus ≤-5%) was selected to classify NPC patients into low RWL and high RWL groups for survival analysis. Compared to high RWL (≤-5%), patients with low RWL (>-5%) had significantly better ten-year DFS (78.6% versus 61.2%; $P < 0.001$), OS (86.6% versus 70.1%; $P < 0.001$), and DMFS (88.5% versus 80.2%; $P = 0.007$). However, no difference was observed between LRRFS groups (91.7% versus 94.3%; $P = 0.173$). In multivariate analysis, RWL ≤-5% was an independent risk factor for DFS (HR, 1.56; 95% CI, 1.19-2.03; $P = 0.001$), OS (HR, 1.54; 95% CI, 1.11-2.15; $P = 0.011$) and DMFS (HR, 1.47; 95% CI, 1.03-2.10; $P = 0.033$) in patients with NPC. Additionally, chemotherapy and old age were attributed to the development of high RWL.

Conclusions: Weight loss during RT was significantly associated with decreased survival among NPC patients. Clinicians should continuously inform patients on the health impact of minimizing weight loss under 5%.

Background

Nasopharyngeal carcinoma (NPC), an epithelial malignancy that is distinguished from other head and neck cancers, is highly prevalent in southern China [1]. The main treatment for NPC is radiotherapy (RT) due to anatomical restrictions and radio-sensitivity. Over the past decade, improved NPC survival can be attributed to advances in imaging techniques, chemotherapy, and radiation technology. However, 20–30% of patients die as a result of NPC recurrence [2–3]. For this reason, efforts to identify modifiable risk factors can potentially provide new insights on developing clinical intervention for increasing long-term survival.

Patients diagnosed with head and neck cancers often experience weight loss during treatment due to acute toxicity, such as mucositis, dysgeusia, xerostomia, and nausea [4–7]. Previous studies [8, 9] have estimated weight loss to range from 40–90%, especially among NPC patients where rates are high. Furthermore, studies have reported poor survival was associated with substantial weight loss during

treatment for patients diagnosed with NPC [10–12]. Compared to other prognostic factors, weight loss can potentially be treated as a therapeutic target that is effectively managed through nutritional support.

During RT, weight loss might be an important parameter to monitor at all treatment phases [13]. Monitoring for decreasing weight at each phase of NPC treatment will allow for clinicians to evaluate the current treatment plan effectiveness, a strategy of “adaptive RT” [14]. Moreover, knowing the dynamic variation of patients’ weight loss during treatment is helpful in selecting the optimal time for nutritional intervention and altering RT treatment. However, bodyweight was only obtained at baseline visit and again at the end of treatment in prior studies [10–12], without considering weight loss during treatment.

To fill the current gaps in knowledge and limitations of previous studies, we conducted a large-scale retrospective study of NPC patients treated with radical RT. The present study sought to (1) draw a dynamic map of weight variation during RT; (2) identify the weight loss prognostic value on survival outcomes; (3) demonstrate risk factors for weight loss; and (4) provide insight on individualized nutritional intervention and the timing of RT replanning for NPC patients.

Methods

Patient characteristics

The present study was a retrospective cohort study utilizing in-patient medical records from Sun Yat-Sen University Cancer Center consisting of first diagnosis of histologically confirmed, non-disseminated NPC from January 2006 to October 2014. We included patients if they met the following criteria: (1) newly diagnosed non-disseminated NPC; (2) Karnofsky performance score ≥ 70 ; (3) no indication of distant metastases; (4) absent of secondary malignancy; (5) treated with radical intensity-modulated radiation therapy (IMRT); and (6) weekly assessment of weight. This study was approved by our institutional ethics committee, and written informed consent was obtained from all participants. The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit (RDD) public platform www.researchdata.org.cn, with the approval RDD number of RDDA2019001296.

The cohort included 1149 patients with NPC, where baseline assessment included full physical examination, fiberoptic nasopharyngoscopy, neck and nasopharyngeal magnetic resonance imaging (MRI), computed tomography (CT), abdominal ultrasonography, biochemistry profiling and hematology, whole body bone scan (ECT) or ^{18}F -fluorodeoxyglucose positron emission tomography and CT (PET-CT). Real-time quantitative polymerase chain reaction was used to measure Plasma Epstein-Barr virus (EBV) DNA concentrations as previously described in detail [15]. We staged NPC patients based on the 7th edition of the American Joint Commission on Cancer (AJCC) staging system [16].

Radiotherapy and chemotherapy

Radical IMRT comprising of five daily fractions were administered to all patients each week for six to seven weeks. Dose prescribed to patients were (1) 66–70 Gy at 2.12–2.27 Gy/fraction to planning target

volume (PTV) of nasopharyngeal gross tumor volume (GTVnx); (2) PTV of GTV of the metastatic lymph nodes (GTVnd) received 64–70 Gy; and (3) high-risk clinical target volume (CTV1) receive 60–63 Gy to PTV and (4) low-risk clinical target volume (CTV2) receive 50–56 Gy to PTV. Stage I disease is generally recommended IMRT only; stage II disease included concurrent chemoradiotherapy (CCRT), and stage III-IVB comprised of CCRT with or without induction chemotherapy (IC).

Concurrent chemotherapy comprised of cisplatin (80 or 100 mg/m²) given in weeks one, four, and seven of RT, starting on the initial day of RT. The IC included cisplatin (60 mg/m²), docetaxel (60 mg/m²), and 5-fluorouracil (600 mg/m²/day over 120 h), or cisplatin (80 mg/m²) plus 5-fluorouracil (800 mg/m²/day over 120 h) or cisplatin (80 mg/m²) plus docetaxel (80 mg/m²) every three weeks for two or three cycles.

Data collection

Patients' age, height, weight, gender, pre-therapy laboratory counts of serum lactate dehydrogenase (LDH), high sensitivity C-reactive protein (hs-CRP), plasma EBV DNA, pathological types, clinical stage, and treatment type were extracted from medical records. Digital electronic scale (XiangShan, EB9871) was used to measure bodyweight to the nearest 0.1 kg in light garment and without shoes. We measured patients' bodyweight at initiation of RT and every week during RT. Bodyweight before RT (W_{Pre-RT}) was measured at initiation of RT, and $W_{RT1,2,3,4,5,6,7}$ (body weight at 1st, 2nd, 3rd, 4th, 5th, 6th, and 7th week of RT) was measured at each week of RT. $RWL_{1,2,3,4,5,6,7}$ was calculated using the following equation: $(W_{RT1,2,3,4,5,6,7} - W_{Pre-RT})/W_{Pre-RT} \times 100\%$. At time of study, all patients were on 100% oral intake, where no type of enteral feeding tube or total parental nutrition were used.

Follow-up and endpoints

Examination of patients were at least in three month increments during the first two years, and six month increments for three years thereafter or until death. Disease-free survival (DFS) was our primary endpoint, defined as time from diagnosis to documented recurrence of disease (either distant metastasis or locoregional disease recurrence) or mortality from any cause, whichever occurred first. Secondary endpoints consisted of (1) distant metastasis free survival (DMFS) (no documented distant metastasis); (2) locoregional relapse free survival (LRRFS) (no documented locoregional recurrence); and (3) overall survival (OS).

Statistical methods

In this study covariates included host factors (e.g. age, gender, tobacco smoking status, hs-CRP, LDH, and EBV DNA), treatment factors (e.g. treatment modality), and tumor factors (e.g. histology, T stage, and N stage). We classified categorical variables based on clinical findings. Determined by routine cutoff points and findings from prior studies, continuous variables were converted to categorical variables [17–19]. χ^2 test or Fisher's Exact test were used to compare clinicopathologic characteristics groups.

Kaplan-Meier method was used to calculate actuarial rates, where we compared differences by utilizing the log-rank test. Optimal RWL threshold was identified by performing recursive partitioning analyses

(RPAs) for the cohort. Univariable with a $P < 0.05$ was used to include covariates in the multivariable model. Using multivariate Cox proportional hazards model, the impact RWL has on survival outcomes were estimated. The rms package in R version 3.3.2 (<http://www.r-project.org/>) were used to perform statistical analysis and generate figures unless otherwise specified. Finally, statistical tests were two-tailed and $P < 0.05$ was considered statistically significant.

Results

Patient characteristics

Clinicopathological characteristics of the 1149 patients are shown in Table 1. Among all patients, 892 (77.6%) were male and 257 (22.4%) female. Majority (1058, 92%) of NPC patients experienced weight loss during RT. When examining by stage, the percentage of patients at stage I, II, III, and IVA-B were 2.1%, 9.9%, 53.7%, and 34.3%, respectively. Overall, 140 (12%) received RT alone and 1009 (88%) received chemotherapy. Of these patients receiving chemotherapy, 549 (48%; 549/1009) received IC plus CCRT and 460 (40%; 460/1009) received CCRT alone. In total, the median follow-up time was 72.6 months (54.8, 6–85.8 months).

Table 1
Baseline patient characteristics according to rate of weight loss (RWL).

| Characteristic | Total (N = 1149) ^a | No. (%) of patients by RWL | | P value |
|-----------------------|-------------------------------|----------------------------|---------------------|---------|
| | | >-5% (n = 402, 35%) | ≤-5% (n = 747, 65%) | |
| Gender | | | | 0.826 |
| Male | 892 (77.6) | 314 (78.1) | 578 (77.4) | |
| Female | 257 (22.4) | 88 (21.2) | 169 (22.6) | |
| Age, y | | | | 0.006 |
| <30 | 68 (5.9) | 28 (7.0) | 40 (5.4) | |
| 30–39 | 263 (22.9) | 96 (23.9) | 167 (22.4) | |
| 40–49 | 447 (38.9) | 143 (35.6) | 304 (40.7) | |
| 50–59 | 227 (19.8) | 67 (16.7) | 160 (21.4) | |
| ≥60 | 144 (12.5) | 68 (16.9) | 76 (10.2) | |
| Histology (WHO) | | | | 0.732 |
| Type I-II | 35 (3.1) | 11 (2.7) | 24 (3.2) | |
| Type III | 1114 (96.9) | 391 (97.3) | 723 (96.8) | |
| Smoking history | | | | 0.996 |
| No | 807 (70.2) | 282 (70.2) | 525 (70.3) | |
| Yes | 342 (29.8) | 120 (29.9) | 222 (29.7) | |
| T stage (7th edition) | | | | 0.031 |
| T1 | 71 (6.2) | 32 (8.0) | 39 (5.2) | |
| T2 | 185 (16.1) | 69 (17.2) | 116 (15.5) | |
| T3 | 627 (54.6) | 226 (56.2) | 401 (53.7) | |
| T4 | 266 (23.2) | 75 (18.7) | 191 (25.6) | |
| N stage (7th edition) | | | | < 0.001 |
| N0 | 128 (11.1) | 59 (14.7) | 69 (9.2) | |

Abbreviations: RWL, rate of weight loss; WHO, World Health Organization; hs-CRP, high sensitivity C-reactive protein; LDH, lactate dehydrogenase; EBV, Epstein-Barr virus;

^a Percentages may not add up to 100 due to rounding.

^b All variables were measured before treatment.

| Characteristic | Total (N = 1149) ^a | No. (%) of patients by RWL | | P value |
|-------------------------------|-------------------------------|----------------------------|------------|---------|
| N1 | 448 (39.0) | 177 (44.0) | 271 (36.3) | |
| N2 | 399 (34.7) | 118 (29.4) | 281 (37.6) | |
| N3 | 174 (15.1) | 48 (11.9) | 126 (16.9) | |
| Overall stage | | | | 0.001 |
| Stage I | 24 (2.1) | 13 (3.2) | 11 (1.5) | |
| Stage II | 114 (9.9) | 53 (13.2) | 61 (8.2) | |
| Stage III | 617 (53.7) | 223 (55.5) | 394 (52.7) | |
| Stage IVA-B | 394 (34.3) | 113 (28.1) | 281 (37.6) | |
| hs-CRP, g/mL ^b | | | | 0.536 |
| <1.0 | 363 (31.6) | 133 (33.1) | 230 (30.8) | |
| 1.0–3.0 | 370 (32.2) | 132 (32.8) | 238 (31.9) | |
| ≥3.0 | 416 (36.2) | 137 (34.1) | 279 (37.4) | |
| LDH, U/L ^b | | | | 0.095 |
| <245 | 1058 (92.1) | 378 (94.0) | 680 (91.0) | |
| ≥245 | 91 (7.9) | 24 (6.0) | 67 (9.0) | |
| EBV DNA, copy/mL ^b | | | | 0.043 |
| <1,000 | 500 (43.5) | 193 (48.0) | 307 (41.1) | |
| 1,000–9,999 | 266 (23.2) | 96 (23.9) | 170 (22.8) | |
| 10,000–99,999 | 268 (23.3) | 82 (20.4) | 186 (24.9) | |
| ≥100,000 | 115 (10.0) | 31 (7.7) | 84 (11.2) | |
| Treatment | | | | < 0.001 |
| RT alone | 140 (12.2) | 81 (20.2) | 59 (7.9) | |
| CCRT alone | 460 (40.0) | 126 (31.3) | 334 (44.7) | |

Abbreviations: RWL, rate of weight loss; WHO, World Health Organization; hs-CRP, high sensitivity C-reactive protein; LDH, lactate dehydrogenase; EBV, Epstein-Barr virus;

^a Percentages may not add up to 100 due to rounding.

^b All variables were measured before treatment.

| Characteristic | Total (N = 1149) ^a | No. (%) of patients by RWL | | P value |
|--|-------------------------------|----------------------------|------------|---------|
| IC + CCRT | 549 (47.8) | 195 (48.5) | 354 (47.4) | |
| Abbreviations: RWL, rate of weight loss; WHO, World Health Organization; hs-CRP, high sensitivity C-reactive protein; LDH, lactate dehydrogenase; EBV, Epstein-Barr virus; | | | | |
| ^a Percentages may not add up to 100 due to rounding. | | | | |
| ^b All variables were measured before treatment. | | | | |

Identification of the optimal cut-off value for defining RWL as high or low

Five- and ten-year DFS, OS, DMFS, and LRRFS rates were 76.3% and 66.8%, 86.0% and 75.3%, 85.9% and 83.1%, and 93.2% and 92.7%, respectively. For the RWL, the optimal cutoff point for DFS among the entire group was - 5.3% based on RPAs. Thus, a uniform cutoff point was selected at -5% (>-5% versus ≤-5%) to classify patients into groups low RWL and high RWL for survival analysis. 63% (725/1149) of patients suffered ≥ 5% weight loss. When comparing survival between groups, our findings showed patients with high RWL had poorer ten-year DFS (61.2% versus 78.5%; $P < 0.001$; Fig. 1A), OS (70.1% versus 86.6%; $P < 0.001$; Fig. 1B), and DMFS (80.2% versus 88.5%; $P = 0.007$; Fig. 1C) compared to low RWL patients. However, no associated difference between groups for ten-year LRRFS (91.7% versus 94.3%; $P = 0.173$; Fig. 1D) was observed. Further analysis revealed that RWL ≤-5% was an independent unfavorable prognostic factor for DFS (HR, 1.56; 95% CI, 1.19–2.03; $P = 0.001$), OS (HR, 1.54; 95% CI, 1.11–2.15; $P = 0.011$) and DMFS (HR, 1.47; 95% CI, 1.03–2.10; $P = 0.033$) in multivariate analysis (Table 2).

Table 2
Multivariate analysis of prognostic factors for patients with NPC (n = 1149).

| Endpoint | Variable | HR | 95% CI for HR | <i>P</i> ^a |
|----------|--------------------|------|---------------|-----------------------|
| DFS | | | | |
| | RWL status | 1.56 | 1.19–2.03 | 0.001 |
| | Age | 1.36 | 1.08–1.71 | 0.010 |
| | Gender | 0.83 | 0.63–1.08 | 0.157 |
| | Pathology | 0.44 | 0.26–0.72 | 0.001 |
| | T stage | 1.62 | 1.16–2.27 | 0.005 |
| | N stage | 1.54 | 1.20–1.97 | 0.001 |
| | EBV DNA | 1.50 | 1.12–2.01 | 0.007 |
| | Treatment strategy | 0.84 | 0.54–1.32 | 0.455 |
| OS | | | | |
| | RWL status | 1.54 | 1.11–2.15 | 0.011 |
| | Age | 1.57 | 1.17–2.10 | 0.002 |
| | Pathology | 0.37 | 0.21–0.66 | 0.001 |
| | T stage | 1.84 | 1.20–2.81 | 0.005 |
| | N stage | 1.72 | 1.26–2.81 | 0.001 |
| | Smoking history | 1.26 | 0.93–1.70 | 0.131 |
| | LDH | 1.27 | 0.80–2.03 | 0.308 |
| | EBV DNA | 1.54 | 1.08–2.21 | 0.018 |
| DMFS | | | | |
| | RWL status | 1.47 | 1.03–2.10 | 0.033 |
| | Age | 1.43 | 1.04–1.96 | 0.026 |
| | Pathology | 0.55 | 0.27–1.13 | 0.104 |
| | T stage | 1.41 | 0.92–2.18 | 0.118 |

Abbreviations: RWL, rate of weight loss; HR, hazard ratio; 95% CI, 95% confidence interval; DFS, disease-free survival; OS, overall survival; DMFS, distant metastasis-free survival; LRRFS, locoregional relapse-free survival; LDH, lactate dehydrogenase; EBV, Epstein-Barr virus.

^a *P* values were calculated using an adjusted Cox proportional hazards model.

| Endpoint | Variable | HR | 95% CI for HR | <i>p</i> ^a |
|---|--------------------|------|---------------|-----------------------|
| | N stage | 1.99 | 1.41–2.80 | < 0.001 |
| | Smoking history | 1.37 | 0.99–1.90 | 0.055 |
| | LDH | 1.33 | 0.82–2.16 | 0.247 |
| | EBV DNA | 2.01 | 1.23–3.30 | 0.006 |
| LRRFS | | | | |
| | Pathology | 0.31 | 0.14–0.72 | 0.006 |
| | Smoking history | 0.56 | 0.31–1.01 | 0.056 |
| | Treatment strategy | 4.86 | 1.17–20.15 | 0.029 |
| Abbreviations: RWL, rate of weight loss; HR, hazard ratio; 95% CI, 95% confidence interval; DFS, disease-free survival; OS, overall survival; DMFS, distant metastasis-free survival; LRRFS, locoregional relapse-free survival; LDH, lactate dehydrogenase; EBV, Epstein-Barr virus. | | | | |
| ^a <i>P</i> values were calculated using an adjusted Cox proportional hazards model. | | | | |

Dynamic variation of body weight during RT

Figure 2 presents the weight loss trend during RT. We observed that RWL remained largely unchanged in the first two weeks of RT, and then began to drop at a relatively stable rate during weeks three to five of RT (from -1.54% to -4.11%; at a rate of -1.3% weight loss per week). At the 6th week of RT, the RWL dropped faster than the prior week (from -4.11% to -5.98%; nearly 2% weight loss in this week). RWL then slowed in the last week of RT (from -5.98% to -6.56%; approximately 0.5% weight loss in this week). Overall, the median weight loss during treatment was -4.0 kg (IQR, -2.0 to -6.0 kg) and the percentage for median weight loss was -6.7% (IQR, -3.5 to -9.7%).

Correlation between RWL and clinicopathological characteristics

Table 1 presents the correlations between clinicopathological characteristics and RWL. High RWL patients were more likely to have advanced TNM stage (advanced T, N, and/or overall stage) ($P < 0.05$ for all). With respect to treatment strategy, the proportion receiving RT alone among the low RWL patient group was associated with higher receipt compared with high RWL (20.2% versus 7.9%; $P < 0.001$). Factors associated with development of high or low RWL were analyzed. After logistic regression analysis, treatment modality and age remained associated with high RWL ($P < 0.05$ for all; Table 3). Additionally, the trend of change in RWL was outlined with treatment patterns and age (Fig. 3). Patients treated with RT alone had the lowest risk with development of weight loss during RT. In contrast, CCRT alone had a significantly strong correlation with the development of weight loss in comparison to RT alone or IC followed by CCRT (OR, 1.71; 95% CI, 1.23–2.31; $P < 0.001$; Fig. S1A). Moreover, patients older

than 45 were more likely to suffer high weight loss than patients age \leq 45 (OR, 1.35; 95% CI, 1.12–1.67; P = 0.002; Fig. S1B) during RT.

Table 3

Multivariate analysis of prognostic factors for the development of high RWL in patients with NPC.

| Variable | HR | 95% CI for HR | Pvalue ^a |
|-------------------------------|-----------|---------------|---------------------|
| Age at diagnosis, y | | | |
| ≤45 | Reference | | |
| >45 | 2.03 | 1.13–3.66 | 0.023 |
| T stage | | | |
| T1 | Reference | | |
| T2 | 0.96 | 0.53–1.73 | 0.908 |
| T3 | 0.87 | 0.50–1.51 | 0.625 |
| T4 | 1.46 | 0.80–2.68 | 0.220 |
| N stage | | | |
| N0 | | | |
| N1 | 1.01 | 0.66–1.55 | 0.952 |
| N2 | 1.52 | 0.95–2.44 | 0.075 |
| N3 | 1.68 | 0.97–2.91 | 0.064 |
| LDH, U/L ^b | | | |
| <245 | Reference | | |
| ≥245 | 1.38 | 0.83–2.29 | 0.232 |
| EBV DNA, copy/mL ^b | | | |
| <1,000 | Reference | | |
| 1,000–9,999 | 0.91 | 0.65–1.28 | 0.604 |
| 10,000–99,999 | 1.11 | 0.78–1.57 | 0.586 |
| ≥100,000 | 1.30 | 0.79–2.12 | 0.315 |
| Treatment | | | |

Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; LDH, lactate dehydrogenase; hs-CRP, high sensitivity C-reactive protein; RT, radiotherapy; CCRT, concurrent chemoradiotherapy; IC + CCRT, induction chemotherapy plus concurrent chemoradiotherapy.

^a P values were calculated using an adjusted Cox proportional hazards model.

^b All variables were measured before treatment.

| Variable | HR | 95% CI for HR | Pvalue ^a |
|---|-----------|---------------|---------------------|
| RT alone | Reference | | |
| CCRT alone | 3.29 | 2.18–4.96 | < 0.001 |
| IC + CCRT | 2.03 | 1.32–3.13 | 0.001 |
| Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval; LDH, lactate dehydrogenase; hs-CRP, high sensitivity C-reactive protein; RT, radiotherapy; CCRT, concurrent chemoradiotherapy; IC + CCRT, induction chemotherapy plus concurrent chemoradiotherapy. | | | |
| ^a P values were calculated using an adjusted Cox proportional hazards model. | | | |
| ^b All variables were measured before treatment. | | | |

Discussion

To the best of our knowledge, this study is the longest follow-up analysis for dynamic variation of weight loss during RT and the associated prognostic value of survival among NPC patients. Results of this present study revealed body weight remained largely unchanged during RT for the first two weeks, and dropped fastest at the sixth week of RT. Further analysis revealed that weight loss $\geq 5\%$ during RT was associated with significantly inferior ten-year DFS, OS, and DMFS for NPC. Additionally, older age and chemotherapy were predictive of greater weight loss for NPC.

Numerous studies have demonstrated that among individuals diagnosed with head and neck cancer, weight loss is correlated with poor prognosis [20, 21], especially among NPC patients [10, 11]. Results from the present study aligned closely with prior studies. There are several potential reasons for these findings. First, critical weight loss may result in loosening of posture fixation, inaccurate radiation field, and significant dosimetric change during IMRT [22]. Second, weight loss potentially causes reduction in treatment tolerance and RT breaks, thus influencing therapeutic efficacy [23, 24]. Third, weight loss is often used as a tool for assessment of newly developed malnutrition, which contributes to weakness in immunity defense mechanism, including phagocyte function, anatomic barriers, cellular and humoral immunity. Therefore, increasing infection susceptibility and reduced response to malignancy [25, 26].

Previous studies reported that weight loss $\geq 5\%$ during RT was associated with poor survival [12, 23]. Our results showed that $RWL \leq -5\%$ was associated with poor DFS, OS, and DMFS, aligning with prior studies. However, Du et al. [11] assessed weight loss during the entire treatment procedure and observed weight loss $\geq 10\%$ was an indicator for likelihood of metastasis and survival. One reason underlying this inconsistency cutoff value of RWL may partly be due to potential selection bias in the study population. Collectively, the impact of weight loss on prognosis of NPC can be determined in the present study. Previous literatures reported approximately 90% local control rates for NPC in the IMRT era [27, 28]. Due to recent advances in RT technology, no observed associated differences in LRRFS between patients in high RWL and low RWL groups were found in the present study. These finding are reasonable as excellent

locoregional control is expected for IMRT, therefore actual impact of weight loss on LRRFS would be limited.

Numerous factors influence weight loss among cancer patients. We observed that patients treated with chemotherapy suffered more weight loss, similar with findings by Qiu et al. [9] and Du et al. [11]. Even with encouraging results attained by multimodal therapy for NPC, acute toxicities are more likely to occur during aggressive chemoradiotherapy [9], including severe oral mucositis, nausea, and vomiting, all directly influencing dietary behavior. Additionally, we observed that patients aged > 60 years had a greater likelihood of suffering higher weight loss. We speculate that elderly patients' reduced organ reserve, multiple comorbidities, and poor treatment tolerance explain the reason for greater weight loss. Other risk factors including radiation technique, segmentation model, and prescribed dose are partly relevant to oral mucositis and weight loss. Given this research adopts the unified radiation technique, segmentation model, and prescribed dose, we did not include the above factors for analysis.

Since weight loss is common among NPC patients, longitudinal studies assessing weight change over RT time is necessary. This is due to potentially providing a more complete understanding on the relationship between bodyweight and survival among NPC patients. However, prior research primarily evaluated weight loss at a single time point, usually pre- or post-treatment. For this reason, limited knowledge exists about the dynamic change of weight loss during RT. Our results indicated that bodyweight remained generally unchanged in the first two weeks of RT, and then began to drop relatively stable the next three weeks, though fastest in the sixth week of RT. The following reasons may explain the observed results. First, the oral mucous membrane reaction of patients is mild and diet is less affected in the first two weeks of RT. With the increasing number of RT, weight loss is gradually accelerated due to oral mucoiditis, aggravated swallowing pain, and decreased treatment tolerance [4].

There are some limitations that must be noted. First, we lacked detailed information on dietary habit and food intake, as well as data on nutritional status was unavailable for further analysis of weight loss. However, during the study period, no standard criteria for nutritional support in patients undergoing RT has been established. Second, the data used in this study derived from only one institution in an endemic area, where a large proportion of physicians have expertise in diagnosing and treating of NPC compared to other nonendemic areas. Third, we failed to include data regarding other prognostic factors, such as smoking and alcohol consumption status. However, to date, there are no prior studies confirming the role of cigarette smoking or alcohol intake during or after treatment on weight loss. Future studies that incorporate external validation and more diverse data are needed.

Conclusion

In conclusion, our findings revealed weight loss decreased fastest during the sixth week of RT. The optimal threshold for RWL adversely impacting NPC prognosis was - 5%. More efforts are needed to be given towards limiting weight loss during RT under 5% in clinical practice as a result of the detrimental impact of RWL on survival outcomes. In addition, use of chemotherapy and old age were attributed to the

development of high weight loss. These findings would be helpful in selecting optimal time for nutritional intervention and RT replanning.

Declarations

Acknowledgments

Not applicable.

Authors' contributions

LX and WH designed the study. YJ, TX, DM, and JY collected the data. LX, YJ, CJ and KP did the data analysis, interpretation, and wrote the report. LX, JY, YY, and LW did the statistical analysis. All authors read and approved the final manuscript.

Funding

This work was supported by grants from the National Natural Science Foundation of China (81901699, 81773051, 81272641 and 81572409) and Guangdong Medical Science and Technology Research Fund (C2018063).

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval and Consent to participate

This study was approved by the institutional review board and ethics committee of Sun Yat-sen University Cancer Center, and written informed consent was obtained from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a "Cantonese cancer"? Chin J Cancer. 2010;29(5):517–26.
2. Mao YP, Tang LL, Chen L, Sun Y, Qi ZY, Zhou GQ, et al. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy. Chin J Cancer.

2016;35(1):103.

3. Sun XS, Liu SL, Luo MJ, Li XY, Chen QY, Guo SS, et al. The Association Between the Development of Radiation Therapy, Image Technology, and Chemotherapy, and the Survival of Patients with Nasopharyngeal Carcinoma: A Cohort Study From 1990 to 2012. *Int J Radiat Oncol Biol Phys*. 2019;105(3):581–90.
4. Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. *Radiother Oncol*. 2003;66(3):253–62.
5. Wu SX, Cui TT, Zhao C, Pan JJ, Xu BY, Tian Y, et al. A prospective, randomized, multi-center trial to investigate Actovegin in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma. *Radiother Oncol*. 2010;97(1):113–8.
6. Luo DH, Hong MH, Guo L, Cao KJ, Deng MQ, Mo HY. Analysis of oral mucositis risk factors during radiotherapy for nasopharyngeal carcinoma patients and establishment of a discriminant model. *Ai Zheng*. 2005;24:850–4.
7. Nishioka T, Shirato H, Arimoto T, Kaneko M, Kitahara T, Oomori K, et al. Reduction of radiation-induced xerostomia in nasopharyngeal carcinoma using CT simulation with laser patient marking and three-field irradiation technique. *Int J Radiat Oncol Biol Phys*. 1997;38(4):705–12.
8. Li G, Jiang XY, Qiu B, Shen LJ, Chen C, Xia YF. Vicious circle of acute radiation toxicities and weight loss predicts poor prognosis for nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy. *J Cancer*. 2017;8(5):832–8.
9. Qiu C, Yang N, Tian G, Liu H. Weight loss during radiotherapy for nasopharyngeal carcinoma: a prospective study from northern China. *Nutr Cancer*. 2011;63(6):873–9.
10. Zeng Q, Shen LJ, Guo X, Guo XM, Qian CN, Wu PH. Critical weight loss predicts poor prognosis in nasopharyngeal carcinoma. *BMC Cancer*. 2016;16:169.
11. Du XJ, Tang LL, Mao YP, Guo R, Sun Y, Lin AH, et al. Value of the prognostic nutritional index and weight loss in predicting metastasis and long-term mortality in nasopharyngeal carcinoma. *J Transl Med*. 2015;13:364.
12. Shen LJ, Chen C, Li BF, Gao J, Xia YF. High weight loss during radiation treatment changes the prognosis in under-/normal weight nasopharyngeal carcinoma patients for the worse: a retrospective analysis of 2433 cases. *PLoS One*. 2013;8(7):e68660.
13. Ho KF, Marchant T, Moore C, Webster G, Rowbottom C, Penington H, et al. Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy. *Int J Radiat Oncol Biol Phys*. 2012;82:e375–82.
14. Jensen AD, Nill S, Huber PE, Bendl R, Debus J, Mütter MW. A clinical concept for interfractional adaptive radiation therapy in the treatment of head and neck cancer. *Int J Radiat Oncol Biol Phys*. 2012;82:590–66.
15. Yao JJ, Lin L, Jin YN, Wang SY, Zhang WJ, Zhang F, et al. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-

- Barr virus DNA. *Cancer Sci.* 2017;108(8):1640–7.
16. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol.* 2010;17:1471–4.
 17. Zhou GQ, Tang LL, Mao YP, Chen L, Li WF, Sun Y, et al. Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. *Int J Radiat Oncol Biol Phys.* 2012;82(3):e359–65.
 18. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. *J Clin Oncol.* 2009;27:2217–24.
 19. Tang LQ, Li CF, Li J, Chen WH, Chen QY, Yuan LX, et al. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. *J Natl Cancer Inst.* 2015;108(1). doi:10.1371/journal.pone.0008660.
 20. Baxi SS, Schwitzer E, Jones LW. A review of weight loss and sarcopenia in patients with head and neck cancer treated with chemoradiation. *Cancers Head Neck.* 2016;1:9. doi:10.1186/s41199-016-0010-0.
 21. Langius JA, Twisk J, Kampman M, Doornaert P, Kramer MH, Weijs PJ, et al. Prediction model to predict critical weight loss in patients with head and neck cancer during (chemo)radiotherapy. *Oral Oncol.* 2016;52:91–6.
 22. Chen C, Fei Z, Chen L, Bai P, Lin X, Pan J. Will weight loss cause significant dosimetric changes of target volumes and organs at risk in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy? *Med Dosim.* 2014;39(1):34–7.
 23. Kubrak C, Olson K, Jha N, Scrimger R, Parliament M, McCargar L, et al. Clinical determinants of weight loss in patients receiving radiation and chemoirradiation for head and neck cancer: a prospective longitudinal view. *Head Neck.* 2013;35(5):695–703.
 24. Yao JJ, Zhang F, Gao TS, Zhang WJ, Lawrence WR, Zhu BT, et al. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. *Radiother Oncol.* 2019;132:178–87.
 25. Datema FR, Ferrier MB, Baatenburg de Jong RJ. Impact of severe malnutrition on short-term mortality and overall survival in head and neck cancer. *Oral Oncol.* 2011;47(9):910–4.
 26. O'Shea D, Cawood TJ, O'Farrelly C, Lynch L. Natural killer cells in obesity: impaired function and increased susceptibility to the effects of cigarette smoke. *PLoS One.* 2010;5(1):e8660.
 27. Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. *Radiother Oncol.* 2014;110(3):398–403.
 28. Yao JJ, Qi ZY, Liu ZG, Jiang GM, Xu XW, Chen SY, et al. Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. *Radiother Oncol.* 2019;137:137–44.

Figures




Figure 1

Comparison between the RWL > -5% group and the RWL ≤ -5% group for disease-free survival (A), overall survival (B), distant metastasis-free survival (C), and locoregional relapse-free survival (D). RWL, rate of weight loss.




Figure 2

Dynamic variation of weight loss at every week during RT in patients with NPC.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Fig.S1.jpg](#)